Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced on Thursday that Phase 3 data results of diabetes treatment pill Tradjenta® (linagliptin) showed marked improvements in African-American blood sugar. The data were presented at the American Association of Clinical Endocrinologists (AACE) 21st annual Scientific and Clinical Congress, and to date, it is the only drug of its kind to be approved at the one-dosage strength level.
SEE ALSO: Will The Real Race-Baiters Stand Up?
Researchers saw a need to address and collect data from the underrepresented data samples of African Americans in order to study how Blacks combat diabetes. This study is the first of its kind, focusing on DPP-4 inhibitors and patients with Type 2 diabetes.
“These findings support the efficacy and safety profile of linagliptin as a treatment option for African-American adult patients with Type 2 diabetes,” said lead investigator James Thrasher, MD, FACE, Arkansas Diabetes and Endocrinology Center. “As there may be differences in response to treatment among ethnic groups, an important finding of this trial is that the results are consistent with the A1C reduction seen in the linagliptin pivotal trials, which included a small sample of African-American patients.”
While Tradjenta is not recommended for persons with Type 1 diabetes, you can learn more about it here.